Axsome Therapeutics (AXSM) – Research Analysts’ Recent Ratings Changes

Axsome Therapeutics (NASDAQ: AXSM) has recently received a number of price target changes and ratings updates:

• 11/25/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
• 11/20/2024 – Axsome Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/13/2024 – Axsome Therapeutics had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an “outperform” rating on the stock.
• 11/12/2024 – Axsome Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/12/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
• 10/4/2024 – Axsome Therapeutics had its price target raised by analysts at Royal Bank of Canada from $130.00 to $131.00. They now have an “outperform” rating on the stock.
• 10/1/2024 – Axsome Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $97.03 on Wednesday. The stock has a market cap of $4.70 billion, a PE ratio of -14.86 and a beta of 1.26. Axsome Therapeutics, Inc. has a 1 year low of $61.14 and a 1 year high of $105.00. The firm has a fifty day moving average price of $91.21 and a 200-day moving average price of $85.47. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the company posted ($1.32) EPS. Equities analysts anticipate that Axsome Therapeutics, Inc. will post -4.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares in the company, valued at $913,282.62. This trade represents a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AXSM. Russell Investments Group Ltd. raised its position in Axsome Therapeutics by 5,550.0% during the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after purchasing an additional 777 shares during the period. Vanguard Group Inc. lifted its position in Axsome Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock worth $298,474,000 after buying an additional 43,512 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Axsome Therapeutics by 136.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 7,370 shares of the company’s stock worth $588,000 after buying an additional 4,258 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Axsome Therapeutics during the first quarter worth $35,000. Finally, Kennedy Capital Management LLC increased its position in Axsome Therapeutics by 46.0% during the first quarter. Kennedy Capital Management LLC now owns 19,483 shares of the company’s stock valued at $1,555,000 after acquiring an additional 6,136 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.